Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

ClinicalTrials.gov ID: NCT00123903

Public ClinicalTrials.gov record NCT00123903. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.

Study identification

NCT ID
NCT00123903
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,220 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2005
Primary completion
Apr 30, 2006
Completion
Apr 30, 2006
Last update posted
Jan 17, 2017

2005 – 2006

United States locations

U.S. sites
72
U.S. states
24
U.S. cities
63
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35213
GSK Investigational Site Mobile Alabama 36617
GSK Investigational Site Phoenix Arizona 85023
GSK Investigational Site Fullerton California 92835
GSK Investigational Site Inglewood California 90301
GSK Investigational Site Los Angeles California 90057
GSK Investigational Site Mission Viejo California 92691
GSK Investigational Site Oakland California 94609
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site Colorado Springs Colorado 80919
GSK Investigational Site Hollywood Florida 33023
GSK Investigational Site Miami Florida 33156
GSK Investigational Site Miami Florida 33169
GSK Investigational Site Pembroke Pines Florida 33024
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site Tampa Florida 33614
GSK Investigational Site Decatur Georgia 30035
GSK Investigational Site Chicago Illinois 60607
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Melrose Park Illinois 60160
GSK Investigational Site Avon Indiana 46123
GSK Investigational Site Elkhart Indiana 46515
GSK Investigational Site Evansville Indiana 47713
GSK Investigational Site Evansville Indiana 47714
GSK Investigational Site Indianapolis Indiana 46250
GSK Investigational Site Indianapolis Indiana 46254
GSK Investigational Site Lafayette Louisiana 70503
GSK Investigational Site Ayer Massachusetts 01432
GSK Investigational Site Worcester Massachusetts 01608
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Voorhees Township New Jersey 08043
GSK Investigational Site Buffalo New York 14222
GSK Investigational Site Camillus New York 13031
GSK Investigational Site East Syracuse New York 13057
GSK Investigational Site Kingston New York 12401
GSK Investigational Site Port Chester New York 10573
GSK Investigational Site Rochester New York 14618
GSK Investigational Site Charlotte North Carolina 28211
GSK Investigational Site Greensboro North Carolina 27401
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Cleveland Ohio 44130
GSK Investigational Site Columbus Ohio 43210-1296
GSK Investigational Site Kettering Ohio 45429
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Oregon City Oregon 97045
GSK Investigational Site Beaver Pennsylvania 15009
GSK Investigational Site Havertown Pennsylvania 19083
GSK Investigational Site Philadelphia Pennsylvania 19152
GSK Investigational Site Reading Pennsylvania 19601
GSK Investigational Site West Grove Pennsylvania 19390
GSK Investigational Site East Providence Rhode Island 02914
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Johnson City Tennessee 37604
GSK Investigational Site Beaumont Texas 77701
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site Dallas Texas 75390-9068
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Galveston Texas 77555-0188
GSK Investigational Site Houston Texas 77024
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Midland Texas 79705
GSK Investigational Site San Antonio Texas 78216
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Burke Virginia 22015
GSK Investigational Site Springfield Virginia 22151
GSK Investigational Site Edmonds Washington 98026
GSK Investigational Site Olympia Washington 98502
GSK Investigational Site Spokane Washington 99206
GSK Investigational Site Spokane Washington 99207
GSK Investigational Site Spokane Washington 99208
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00123903, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2017 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00123903 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →